For the fiscal quarter ending June 30 2023, BRUKER CORPORATION ($NASDAQ:BRKR) reported total revenue of USD 681.9 million and net income of USD 57.1 million – a 15.9% and 15.4% year-over-year increase, respectively.
GoodWhale has conducted an analysis of the fundamental data of BRUKER CORPORATION and the results are very positive. The Star Chart ratings awarded to the company are a 9/10, indicating that its cashflows and debt are strong and it is capable of riding out any crisis without the risk of bankruptcy. Furthermore, BRUKER CORPORATION’s assets, dividend, growth, and profitability are all highly rated, making it a very attractive investment option. Based on this data, BRUKER CORPORATION is classified as a ‘gorilla’, meaning that they have achieved stable and high revenue or earning growth due to their strong competitive advantage. This makes them a great option for investors who are looking for a long-term, stable return on their investments. Those with a higher risk tolerance may be interested in taking advantage of the opportunities that BRUKER CORPORATION offers, as it has proven itself to be a reliable and profitable company over the years. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Bruker Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bruker Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bruker Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Bruker Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Its products are used in a variety of applications, including drug discovery, food and environmental testing, and materials science research. The company’s main competitors are Tecan Group AG, Stevanato Group SPA, and Cerus Corporation.
– Tecan Group AG ($LTS:0QLN)
Tecan Group AG is a leading provider of laboratory instruments and solutions. The company has a market cap of 4.56B as of 2022 and a Return on Equity of 6.13%. Tecan provides a wide range of products and services for the life science research, diagnostics and pharmaceutical sectors. The company offers a broad range of solutions for drug discovery, genomics, diagnostics and forensics. Tecan also provides contract research services to the pharmaceutical industry.
– Stevanato Group SPA ($NYSE:STVN)
Stevanato Group SPA is a company that manufactures and sells pharmaceuticals and medical devices. The company has a market cap of 4.89B as of 2022 and a return on equity of 11.0%. The company’s products are sold in over 100 countries and it has a presence in Europe, North America, and Asia.
Cerus Corp is a medical technology company that specializes in blood safety. The company’s primary product is the Intercept Blood System, which is designed to inactivate viruses, bacteria, parasites, and other potentially harmful agents in donated blood. Cerus Corp’s market cap as of 2022 is 625.13M, and its ROE is -28.3%. The company has been facing some financial difficulties in recent years, but continues to invest in research and development in order to bring new products to market.
Investors in Bruker Corporation have reason to be optimistic as the company reported record-breaking total revenue of USD 681.9 million and net income of USD 57.1 million for the second quarter of FY2023, ending June 30, 2023. These figures signify a year-over-year increase of 15.9% and 15.4%, respectively. Despite the positive financial results, the stock price moved down on the same day, possibly due to profit taking or market conditions. Nonetheless, the strong financial performance signals that investors should keep an eye on Bruker Corporation for potential long-term gains.